New drug cocktail takes on rare lymphoma

NCT ID NCT06421948

First seen Jan 05, 2026 · Last updated May 05, 2026 · Updated 15 times

Summary

This study tests a new combination of two targeted drugs (linperlisib and chidamide) against standard chemotherapy for people with peripheral T-cell lymphoma, a rare blood cancer. The trial involves about 134 adults aged 18-80. The goal is to see if the new combo works better at controlling the cancer and has fewer side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIPHERAL T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Affiliated Cancer Hospital of Zhengzhou University

    RECRUITING

    Zhengzhou, Henan, 450008, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Cong Li

    RECRUITING

    Hangzhou, Zhejiang, 310000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Huilai Zhang

    RECRUITING

    Tianjin, Tianjin Municipality, 300060, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Liling Zhang

    RECRUITING

    Wuhan, Hubei, 430022, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Ming Jiang

    RECRUITING

    Chengdu, Sichuan, 610041, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Yajun Li

    RECRUITING

    Changsha, Hunan, 410003, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.